163 related articles for article (PubMed ID: 29339269)
1. Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150).
Jung SH; Lee JJ; Kim JS; Min CK; Kim K; Choi Y; Eom HS; Joo YD; Kim SH; Kwak JY; Kang HJ; Lee JH; Lee HS; Mun YC; Moon JH; Sohn SK; Park SK; Park Y; Shin HJ; Yoon SS;
Biol Blood Marrow Transplant; 2018 May; 24(5):923-929. PubMed ID: 29339269
[TBL] [Abstract][Full Text] [Related]
2. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.
Nieto Y; Thall P; Valdez B; Andersson B; Popat U; Anderlini P; Shpall EJ; Bassett R; Alousi A; Hosing C; Kebriaei P; Qazilbash M; Frazier E; Gulbis A; Chancoco C; Bashir Q; Ciurea S; Khouri I; Parmar S; Shah N; Worth L; Rondon G; Champlin R; Jones RB
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1677-86. PubMed ID: 22643322
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma.
Reece D; Song K; LeBlanc R; Mezzi K; Olujohungbe A; White D; Zaman F; Belch A
Oncologist; 2013; 18(5):611-8. PubMed ID: 23628980
[TBL] [Abstract][Full Text] [Related]
4. A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL).
Visram A; Hayman SR; Dispenzieri A; Kapoor P; Lacy MQ; Gertz MA; Buadi FK; Dingli D; Warsame R; Kourelis T; Cook J; Binder M; Gonsalves W; Muchtar E; Leung N; Roy V; Rajkumar SV; Kumar S
Am J Hematol; 2023 Aug; 98(8):1277-1285. PubMed ID: 37334773
[TBL] [Abstract][Full Text] [Related]
5. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.
Nath CE; Trotman J; Tiley C; Presgrave P; Joshua D; Kerridge I; Kwan YL; Gurney H; McLachlan AJ; Earl JW; Nivison-Smith I; Zeng L; Shaw PJ
Br J Clin Pharmacol; 2016 Jul; 82(1):149-59. PubMed ID: 26879446
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma.
Lee SR; Kim SJ; Park Y; Sung HJ; Choi CW; Kim BS
Korean J Hematol; 2010 Sep; 45(3):183-7. PubMed ID: 21120207
[TBL] [Abstract][Full Text] [Related]
7. Impact of melphalan day -1 vs day -2 on outcomes after autologous stem cell transplant for multiple myeloma.
Merino A; Shanley R; Rashid F; Langer J; Dolan M; Tu S; Jurdi NE; Rogosheske J; Hanna K; DeFor T; Janakiram M; Weisdorf D
Front Immunol; 2024; 15():1310752. PubMed ID: 38504993
[TBL] [Abstract][Full Text] [Related]
8. Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
Bygrave C; Pawlyn C; Davies F; Craig Z; Cairns D; Hockaday A; Jenner M; Cook G; Drayson M; Owen R; Gregory W; Morgan G; Jackson G; Kaiser M
Br J Haematol; 2021 May; 193(3):551-555. PubMed ID: 32524584
[TBL] [Abstract][Full Text] [Related]
9. Correction to "A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)".
Am J Hematol; 2024 Jun; ():. PubMed ID: 38837272
[No Abstract] [Full Text] [Related]
10. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Siegel DS; Dimopoulos MA; Ludwig H; Facon T; Goldschmidt H; Jakubowiak A; San-Miguel J; Obreja M; Blaedel J; Stewart AK
J Clin Oncol; 2018 Mar; 36(8):728-734. PubMed ID: 29341834
[TBL] [Abstract][Full Text] [Related]
11. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update.
Anderson K; Ismaila N; Flynn PJ; Halabi S; Jagannath S; Ogaily MS; Omel J; Raje N; Roodman GD; Yee GC; Kyle RA
J Clin Oncol; 2018 Mar; 36(8):812-818. PubMed ID: 29341831
[TBL] [Abstract][Full Text] [Related]
12. Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in Japan.
Muta T; Miyamoto T; Kamimura T; Kanda Y; Nohgawa M; Ueda Y; Iwato K; Sasaki O; Mori T; Uchida N; Iida S; Fukuda T; Atsuta Y; Sunami K
Acta Haematol; 2018; 139(1):35-44. PubMed ID: 29339642
[TBL] [Abstract][Full Text] [Related]
13. Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.
Costa LJ; Landau HJ; Chhabra S; Hari P; Innis-Shelton R; Godby KN; Hamadani M; Tamari R; Anderton K; Dixon P; Giralt SA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1379-1385. PubMed ID: 29410301
[TBL] [Abstract][Full Text] [Related]
14. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
Gössi U; Jeker B; Mansouri Taleghani B; Bacher U; Novak U; Betticher D; Egger T; Zander T; Pabst T
Hematol Oncol; 2018 Apr; 36(2):436-444. PubMed ID: 29363149
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.
Merz M; Jauch A; Hielscher T; Bochtler T; Schönland SO; Seckinger A; Hose D; Bertsch U; Neben K; Raab MS; Hillengass J; Salwender H; Blau IW; Lindemann HW; Schmidt-Wolf IGH; Scheid C; Haenel M; Weisel KC; Goldschmidt H
Blood Adv; 2018 Jan; 2(1):1-9. PubMed ID: 29344579
[TBL] [Abstract][Full Text] [Related]
16. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
[TBL] [Abstract][Full Text] [Related]
17. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.
Garderet L; Iacobelli S; Koster L; Goldschmidt H; Johansson JE; Bourhis JH; Krejci M; Leleu X; Potter M; Blaise D; Koenecke C; Peschel C; Radocha J; Metzner B; Lenain P; Schäfer-Eckart K; Pohlreich D; Grasso M; Caillot D; Einsele H; Ladetto M; Schönland S; Kröger N
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1372-1378. PubMed ID: 29408334
[TBL] [Abstract][Full Text] [Related]
18. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.
Dimopoulos M; Weisel K; van de Donk NWCJ; Ramasamy K; Gamberi B; Streetly M; Offidani M; Bridoux F; de la Rubia J; Mateos MV; Ardizzoia A; Kueenburg E; Collins S; Di Micco A; Rosettani B; Li Y; Bacon P; Sonneveld P
J Clin Oncol; 2018 Jul; 36(20):2035-2043. PubMed ID: 29394124
[TBL] [Abstract][Full Text] [Related]
19. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Matsumura-Kimoto Y; Kuroda J; Kaneko H; Kamitsuji Y; Fuchida SI; Nakaya A; Shibayama H; Uoshima N; Yokota I; Uchiyama H; Yagi H; Kosugi S; Matsui T; Ishikawa J; Matsuda M; Ohta K; Iida M; Tanaka H; Kobayashi M; Wada K; Shimazaki C; Nomura S; Imada K; Hino M; Matsumura I; Kanakura Y; Takaori-Kondo A;
Int J Hematol; 2018 May; 107(5):541-550. PubMed ID: 29380179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
